Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Impact of Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Dual Infection on Female Genital Tract Mucosal Immunity and the Vaginal Microbiome.

Keller MJ, Huber A, Espinoza L, Serrano MG, Parikh HI, Buck GA, Gold JA, Wu Y, Wang T, Herold BC.

J Infect Dis. 2019 Apr 27. pii: jiz203. doi: 10.1093/infdis/jiz203. [Epub ahead of print]

PMID:
31111902
2.

Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection.

Murphy K, Keller MJ, Anastos K, Sinclair S, Devlin JC, Shi Q, Hoover DR, Starkman B, McGillick J, Mullis C, Minkoff H, Dominguez-Bello MG, Herold BC.

PLoS One. 2019 Apr 26;14(4):e0216049. doi: 10.1371/journal.pone.0216049. eCollection 2019.

3.

The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition.

Thurman A, Chandra N, Schwartz JL, Brache V, Chen BA, Asin S, Rollenhagen C, Herold BC, Fichorova RN, Hillier SL, Weiner DH, Mauck C, Doncel GF.

AIDS Res Hum Retroviruses. 2019 May 14. doi: 10.1089/AID.2018.0298. [Epub ahead of print]

PMID:
30997816
4.

Clinical Vignettes: Donor-Derived Infections.

Sharma TS, Michaels MG, Danziger-Isakov L, Herold BC.

J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S67-S71. doi: 10.1093/jpids/piy129.

PMID:
30590624
5.

A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection.

Nelson CS, Herold BC, Permar SR.

NPJ Vaccines. 2018 Sep 20;3:38. doi: 10.1038/s41541-018-0074-4. eCollection 2018. Review.

6.

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.

Taneva E, Sinclair S, Mesquita PM, Weinrick B, Cameron SA, Cheshenko N, Reagle K, Frank B, Srinivasan S, Fredricks D, Keller MJ, Herold BC.

JCI Insight. 2018 Jul 12;3(13). pii: 99545. doi: 10.1172/jci.insight.99545.

7.

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, Marzinke MA, Stanczyk FZ, Dezzutti CS, Hillier SL, Herold BC, Fichorova R, Asin SN, Rollenhagen C, Weiner D, Kiser P, Doncel GF.

PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018.

8.

A Multicenter Consortium to Define the Epidemiology and Outcomes of Pediatric Solid Organ Transplant Recipients With Inpatient Respiratory Virus Infection.

Danziger-Isakov L, Steinbach WJ, Paulsen G, Munoz FM, Sweet LR, Green M, Michaels MG, Englund JA, Murray A, Halasa N, Dulek DE, Madan RP, Herold BC, Fisher BT.

J Pediatric Infect Dis Soc. 2018 Mar 10. doi: 10.1093/jpids/piy024. [Epub ahead of print]

PMID:
29538674
9.

Low Birth Weight in Human Immunodeficiency Virus-Exposed Uninfected Infants in Bronx, New York.

Dara JS, Hanna DB, Anastos K, Wright R, Herold BC.

J Pediatric Infect Dis Soc. 2018 May 15;7(2):e24-e29. doi: 10.1093/jpids/pix111.

10.

Herpes simplex viruses activate phospholipid scramblase to redistribute phosphatidylserines and Akt to the outer leaflet of the plasma membrane and promote viral entry.

Cheshenko N, Pierce C, Herold BC.

PLoS Pathog. 2018 Jan 2;14(1):e1006766. doi: 10.1371/journal.ppat.1006766. eCollection 2018 Jan.

11.

A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.

Burn C, Ramsey N, Garforth SJ, Almo S, Jacobs WR Jr, Herold BC.

J Infect Dis. 2018 Feb 14;217(5):754-758. doi: 10.1093/infdis/jix628.

12.

US6 Gene Deletion in Herpes Simplex Virus Type 2 Enhances Dendritic Cell Function and T Cell Activation.

Retamal-Díaz A, Weiss KA, Tognarelli EI, Freire M, Bueno SM, Herold BC, Jacobs WR Jr, González PA.

Front Immunol. 2017 Nov 10;8:1523. doi: 10.3389/fimmu.2017.01523. eCollection 2017.

13.

A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Fisher BT, Danziger-Isakov L, Sweet LR, Munoz FM, Maron G, Tuomanen E, Murray A, Englund JA, Dulek D, Halasa N, Green M, Michaels MG, Madan RP, Herold BC, Steinbach WJ.

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):275-282. doi: 10.1093/jpids/pix051.

PMID:
29106589
14.

Microbiota control immune regulation in humanized mice.

Gülden E, Vudattu NK, Deng S, Preston-Hurlburt P, Mamula M, Reed JC, Mohandas S, Herold BC, Torres R, Vieira SM, Lim B, Herazo-Maya JD, Kriegel M, Goodman AL, Cotsapas C, Herold KC.

JCI Insight. 2017 Nov 2;2(21). pii: 91709. doi: 10.1172/jci.insight.91709.

15.

Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIVSF162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings.

Srinivasan P, Zhang J, Dinh CT, Teller RS, McNicholl JM, Kiser PF, Herold BC, Smith JM.

J Med Primatol. 2017 Aug;46(4):129-136. doi: 10.1111/jmp.12299.

PMID:
28748662
16.

Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy.

Nabi R, Moldoveanu Z, Wei Q, Golub ET, Durkin HG, Greenblatt RM, Herold BC, Nowicki MJ, Kassaye S, Cho MW, Pinter A, Landay AL, Mestecky J, Kozlowski PA.

PLoS One. 2017 Jul 3;12(7):e0180245. doi: 10.1371/journal.pone.0180245. eCollection 2017.

17.

Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women.

Thurman AR, Yousefieh N, Chandra N, Kimble T, Asin S, Rollenhagen C, Anderson SM, Herold BC, Freiermuth JL, Starkman BS, Mesquita PMM, Richardson-Harman N, Cunningham T, Hillier S, Rabe L, Schwartz JL, Doncel GF.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):807-819. doi: 10.1089/AID.2016.0320. Epub 2017 May 16.

18.

Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Mesquita PMM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC.

J Infect Dis. 2017 Feb 15;215(4):614-622. doi: 10.1093/infdis/jiw612.

19.

HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Petro CD, Weinrick B, Khajoueinejad N, Burn C, Sellers R, Jacobs WR Jr, Herold BC.

JCI Insight. 2016 Aug 4;1(12). pii: e88529.

20.

Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.

Taneva E, Crooker K, Park SH, Su JT, Ott A, Cheshenko N, Szleifer I, Kiser PF, Frank B, Mesquita PM, Herold BC.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1667-75. doi: 10.1128/AAC.02793-15.

21.

Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women.

Buckley N, Huber A, Lo Y, Castle PE, Kemal K, Burk RD, Strickler HD, Einstein MH, Young M, Anastos K, Herold BC.

Am J Reprod Immunol. 2016 Feb;75(2):146-54. doi: 10.1111/aji.12461. Epub 2015 Dec 18.

22.

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.

Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.

AIDS. 2016 Mar 13;30(5):743-51. doi: 10.1097/QAD.0000000000000979.

23.

An innate antiviral pathway acting before interferons at epithelial surfaces.

Iversen MB, Reinert LS, Thomsen MK, Bagdonaite I, Nandakumar R, Cheshenko N, Prabakaran T, Vakhrushev SY, Krzyzowska M, Kratholm SK, Ruiz-Perez F, Petersen SV, Goriely S, Bibby BM, Eriksson K, Ruland J, Thomsen AR, Herold BC, Wandall HH, Frische S, Holm CK, Paludan SR.

Nat Immunol. 2016 Feb;17(2):150-8. doi: 10.1038/ni.3319. Epub 2015 Nov 30.

PMID:
26595890
24.

Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.

Herold BC, Chen BA, Salata RA, Marzinke MA, Kelly CW, Dezzutti CS, McGowan I, Galaska B, Levy L, Piper JM, Hillier S, Hendrix CW.

Clin Infect Dis. 2016 Feb 1;62(3):375-382. doi: 10.1093/cid/civ913. Epub 2015 Oct 27.

25.

Loss of Innate Host Defense Following Unprotected Vaginal Sex.

Nakra NA, Madan RP, Buckley N, Huber AM, Freiermuth JL, Espinoza L, Walsh J, Parikh UM, Penrose KJ, Keller MJ, Herold BC.

J Infect Dis. 2016 Mar 1;213(5):840-7. doi: 10.1093/infdis/jiv488. Epub 2015 Oct 13.

26.

Neonatal Herpes Infection Associated With Direct Orogenital Suction During Ritual Jewish Circumcision.

Pellett Madan R, Herold BC, Ratner AJ, Saiman L, Gershon AA, Stanberry LR.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):283-4. doi: 10.1093/jpids/piv021. Epub 2015 Apr 24. No abstract available.

27.

Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.

Boukhvalova M, McKay J, Mbaye A, Sanford-Crane H, Blanco JC, Huber A, Herold BC.

J Virol. 2015 Oct;89(19):9825-40. doi: 10.1128/JVI.01387-15. Epub 2015 Jul 15.

28.

Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.

Pellett Madan R, Dezzutti CS, Rabe L, Hillier SL, Marrazzo J, McGowan I, Richardson BA, Herold BC; Microbicide Trials Network Biomedical Sciences working Group and the MTN 004 Protocol Team.

Am J Reprod Immunol. 2015 Oct;74(4):323-32. doi: 10.1111/aji.12412. Epub 2015 Jun 26.

29.

Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.

Murphy K, Richardson BA, Dezzutti CS, Marrazzo J, Hillier SL, Hendrix CW, Herold BC.

Am J Reprod Immunol. 2015 Oct;74(4):313-22. doi: 10.1111/aji.12411. Epub 2015 Jun 21.

30.

Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition.

Pellett Madan R, Masson L, Tugetman J, Werner L, Grobler A, Mlisana K, Lo Y, Che D, Arnold KB, Abdool Karim SS, Passmore JA, Herold BC.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1153-9. doi: 10.1089/AID.2015.0011. Epub 2015 Jul 14.

31.

Dynasore disrupts trafficking of herpes simplex virus proteins.

Mues MB, Cheshenko N, Wilson DW, Gunther-Cummins L, Herold BC.

J Virol. 2015 Jul;89(13):6673-84. doi: 10.1128/JVI.00636-15. Epub 2015 Apr 15.

32.

Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk.

Irvin SC, Herold BC.

PLoS One. 2015 Mar 23;10(3):e0121135. doi: 10.1371/journal.pone.0121135. eCollection 2015.

33.

Multipurpose prevention technologies: the future of HIV and STI protection.

Fernández-Romero JA, Deal C, Herold BC, Schiller J, Patton D, Zydowsky T, Romano J, Petro CD, Narasimhan M.

Trends Microbiol. 2015 Jul;23(7):429-436. doi: 10.1016/j.tim.2015.02.006. Epub 2015 Mar 7. Review.

34.

Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Petro C, González PA, Cheshenko N, Jandl T, Khajoueinejad N, Bénard A, Sengupta M, Herold BC, Jacobs WR.

Elife. 2015 Mar 10;4. doi: 10.7554/eLife.06054.

35.

Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays.

Costantini LM, Irvin SC, Kennedy SC, Guo F, Goldstein H, Herold BC, Snapp EL.

Virology. 2015 Feb;476:240-248. doi: 10.1016/j.virol.2014.12.019. Epub 2014 Dec 30.

36.

Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use.

Srinivasan P, Dinh C, Zhang J, Pau CP, McNicholl JM, Lo Y, Herold BC, Teller R, Kiser P, Smith JM.

J Med Primatol. 2014 Oct;43(5):364-9.

37.

Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.

Smith JM, Srinivasan P, Teller RS, Lo Y, Dinh CT, Kiser PF, Herold BC.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):1-5. doi: 10.1097/QAI.0000000000000402.

38.

Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women.

Penrose KJ, Richardson BA, Besson G, Dezzutti CS, Herold BC, Abdool Karim SS, Mellors JW, Parikh UM; MTN Biomedical Sciences Working Group and the HPTN 035 Protocol Team.

Sex Transm Dis. 2014 Nov;41(11):674-9. doi: 10.1097/OLQ.0000000000000191.

39.

Herpes simplex virus type 2 glycoprotein H interacts with integrin αvβ3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells.

Cheshenko N, Trepanier JB, González PA, Eugenin EA, Jacobs WR Jr, Herold BC.

J Virol. 2014 Sep 1;88(17):10026-38. doi: 10.1128/JVI.00725-14. Epub 2014 Jun 18.

40.

In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Rodríguez A, Kleinbeck K, Mizenina O, Kizima L, Levendosky K, Jean-Pierre N, Villegas G, Ford BE, Cooney ML, Teleshova N, Robbiani M, Herold BC, Zydowsky T, Fernández Romero JA.

Antiviral Res. 2014 Aug;108:88-93. doi: 10.1016/j.antiviral.2014.05.018. Epub 2014 Jun 5.

41.

A pilot program to evaluate deceased donor disease transmission risk: the New York Organ Donor Network Infectious Disease Working Group.

Pellett Madan R, Delli Carpini K, Huprikar S, Lerner H, Patel G, Ratner LE, Goldstein MJ, Herold BC; New York Organ Donor Network Infectious Disease Working Group.

Transplantation. 2014 Oct 27;98(8):909-15. doi: 10.1097/TP.0000000000000152.

PMID:
24879385
42.

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.

Clin Pharmacol Ther. 2014 Sep;96(3):314-23. doi: 10.1038/clpt.2014.118. Epub 2014 May 26.

PMID:
24862215
43.

Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli.

Ghartey JP, Smith BC, Chen Z, Buckley N, Lo Y, Ratner AJ, Herold BC, Burk RD.

PLoS One. 2014 May 7;9(5):e96659. doi: 10.1371/journal.pone.0096659. eCollection 2014.

44.

Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer.

Ghartey J, Kovacs A, Burk RD, Stewart Massad L, Minkoff H, Xie X, Dʼsouza G, Xue X, Heather Watts D, Levine AM, Einstein MH, Colie C, Anastos K, Eltoum IE, Herold BC, Palefsky JM, Strickler HD.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):316-23. doi: 10.1097/QAI.0000000000000157.

45.

Research gaps in defining the biological link between HIV risk and hormonal contraception.

Murphy K, Irvin SC, Herold BC.

Am J Reprod Immunol. 2014 Aug;72(2):228-35. doi: 10.1111/aji.12209. Epub 2014 Feb 19. Review.

46.

Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.

Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):65-73. doi: 10.1097/QAI.0000000000000110.

47.

Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.

Ursell LK, Gunawardana M, Chang S, Mullen M, Moss JA, Herold BC, Keller MJ, McDonald D, González A, Knight R, Baum MM.

Antiviral Res. 2014 Feb;102:87-94. doi: 10.1016/j.antiviral.2013.12.004. Epub 2013 Dec 19.

48.

Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.

Nixon B, Jandl T, Teller RS, Taneva E, Wang Y, Nagaraja U, Kiser PF, Herold BC.

Antimicrob Agents Chemother. 2014;58(2):1153-60. doi: 10.1128/AAC.01818-13. Epub 2013 Dec 9.

49.

Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials.

van der Straten A, Cheng H, Mensch B, Friedland B, Katzen L, Littlefield S, Buckley N, Espinoza L, Keller MJ, Herold BC, Einstein MH.

Sex Transm Dis. 2013 Dec;40(12):950-6. doi: 10.1097/OLQ.0000000000000053.

50.

Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex.

Keller MJ, Buckley N, Katzen LL, Walsh J, Friedland B, Littlefield S, Lin J, Xue X, Cornelison T, Herold BC, Einstein MH.

Sex Transm Dis. 2013 Dec;40(12):939-43. doi: 10.1097/OLQ.0000000000000040.

Supplemental Content

Loading ...
Support Center